Abstracts tagged "Aging"

Abstract Number: 0268 • ACR Convergence 2022
Risks of Mortality in Elderly-onset Rheumatoid Arthritis: Analysis from the TRA Clinical Electronic Registry
Ching-Tsai Lin¹, Wen-Nan Huang¹, Yi-Hsin Chen² and Yi-Ming Chen³, ¹Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ²Taichung Veterans General Hospital, Taichung, Taiwan, ³Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan
Background/Purpose: Patients with rheumatoid arthritis (RA) were associated with increased mortality rate. Our study aimed to investigate the risk factors associated with all causes of…
Abstract Number: 0281 • ACR Convergence 2022
Clinical Outcomes of Filgotinib in Patients with RA Aged ≥65 Years: A Post Hoc Subgroup Analysis of Phase 2 and 3 Clinical Trials and Ongoing Long-Term Extensions
Maya Buch¹, BERNARD COMBE², Jose A Gomez-Puerta³, Roberto Felice Caporali⁴, jacques-eric gottenberg⁵, Paul Van Hoek⁶, Vijay Rajendran⁷, Pieter-Jan Stiers⁶, Katrien Van Beneden⁶, Daniel Aletaha⁸, Gerd Burmester⁹, Rene Westhovens¹⁰ and Yoshiya Tanaka¹¹, ¹University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ²Montpellier University, Montpellier, France, ³Hospital Clínic de Barcelona, Barcelona, Spain, ⁴University of Milan, Milano, Italy, ⁵Strasbourg University Hospital, Strasbourg, France, ⁶Galapagos NV, Mechelen, Belgium, ⁷Galapagos NV, Gent, Belgium, ⁸Medical University Vienna, Wien, Austria, ⁹Charité University Medicine Berlin, Berlin, Germany, ¹⁰University Hospitals Leuven, Leuven, Belgium, ¹¹University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan
Background/Purpose: Filgotinib (FIL) is a Janus kinase 1 preferential inhibitor approved for the treatment of moderate to severe active RA.1 It was previously reported that…
Abstract Number: 0529 • ACR Convergence 2022
Complex Relationships Between Inflammation and Clonal Hematopoiesis in Systemic Vasculitis
Adrianna Jones¹, Kristina Wells¹, Fernanda Gutierrez-Rodrigues², Cameron Rankin³, Wanxia Tsai³, Bhavisha Patel⁴, Kaitlin Quinn¹, Dalton Hironaka², Massimo Gadina⁵, Keith Sikora¹, Neal Young² and Peter Grayson⁶, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ³NIAMS/NIH, Bethesda, MD, ⁴National Institutes of Health, Beltsville, MD, ⁵Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Clonal hematopoiesis of indeterminate potential (CHIP) is defined by somatic mutations in a set of genes commonly associated with myeloid neoplasms in an otherwise…
Abstract Number: 0574 • ACR Convergence 2022
Osteoporosis in Elderly Men; An Underestimated and Underdiagnosed Morbid Entity
Arash Mollaeian¹ and Stanley Ballou², ¹Metro Health Medical Center/Case Western Reserve University, Rocky River, OH, ²Case Western Reserve University - Metro Health, Cleveland, OH
Background/Purpose: 20-25% of osteoporosis-related fractures occur in men and the mortality of osteoporotic fractures is higher in men [1]. Nevertheless, no uniform consensus exists for…
Abstract Number: 1091 • ACR Convergence 2021
Serum Metabolomic Profiling Identifies Potential Biomarkers in Arthritis in the Elderly
Martha Cedeno¹, Jessica Murillo Saich¹, Roxana Coras², Anahy Maria Brandy-Garcia³, Agueda Prior-Español⁴, Lourdes Mateo⁵, Melania Martinez-Morillo⁵ and Monica Guma⁶, ¹University of California San Diego, La Jolla, CA, ²University of California San Diego/Department of Medicine, Autonomous University of Barcelona, San Diego, CA, ³Hospital Germans Trias i Pujol, Badalona, Spain, ⁴Department of Rheumatology, Germans Trias i Pujol. University Hospital, Badalona, Spain, ⁵Department of Rheumatology, Germans Trias i Pujol. University Hospital, Barcelona, Spain, ⁶University of California San Diego/San Diego VA Healthcare Service/Department of Medicine, Autonomous University of Barcelona, La Jolla, CA
Background/Purpose: Elderly-onset RA (EORA) and polymyalgia rheumatica (PMR) are common rheumatic diseases in the elderly, but their pathogenesis is not yet fully understood. Seronegative EORAneg…
Abstract Number: 1145 • ACR Convergence 2021
Prevalence of and Risk Factors for Vertebral Fractures and Low Bone Mass Density Among Women Aging with HIV in Peru
Diego Cabrera¹, Mijahil P. Cornejo², Rebecca Slotkin³, Yvett Pinedo⁴, Wei Yu⁵, Wenmin Guan⁵, Patricia J. Garcia⁶ and Evelyn Hsieh⁷, ¹Yale School of Medicine, Lima, Peru, ²Grunenthal peruana, Lima, Peru, ³Yale New Haven Hospital, New Haven, CT, ⁴Hospital Nacional Arzobispo Loayza, Lima, Peru, ⁵Department of Radiology, Chinese Academy of Medicine Sciences and Peking Union Medical College Hospital, Beijing, China (People's Republic), ⁶Universidad Peruana Cayetano Heredia, Lima, Peru, ⁷Yale School of Medicine, New Haven, CT
Background/Purpose: Few studies in Latin America and the Caribbean have evaluated osteoporosis and fracture epidemiology among populations at increased risk for secondary osteoporosis, such as…
Abstract Number: 1147 • ACR Convergence 2021
Therapeutic Inertia and Low Patient Compliance: Major Contributors to Low Treatment Rates in Patients with Osteoporosis with Clinical Vertebral Compression Fractures
Shiva Malaty, Paramvir Sidhu, Rustan Sharer and Soo Yeon Kim, HonorHealth Internal Medicine Residency, Scottsdale, AZ
Background/Purpose: Treatment rates with pharmacologic therapy after osteoporotic vertebral fracture are very low in the United States. Underlying causes of these low treatment rates are…
Abstract Number: 1392 • ACR Convergence 2021
Assessment of a Patient Self-Report Frailty Tool in Patients with Polymyalgia Rheumatica
Sebastian Sattui, Deanna Jannat-Khah, Lindsay Lally, Sarah Lieber, Lisa Mandl and Robert Spiera, Hospital for Special Surgery, New York, NY
Background/Purpose: Frailty, a syndrome characterized by decreased physiologic reserve, is associated with chronic inflammation. We have shown a high prevalence of frailty in patients with…
Abstract Number: 1514 • ACR Convergence 2021
Age-related Metabolic Reprogramming of Memory CD4+ T Cells Is Associated with Reactive Oxygen Species-induced Immune Cell Dysfunction
Yuling Chen¹, Pierre-Louis Krau², Pelle Löwe³, Moritz Pfeiffenberger⁴, Lisa Ehlers³, Alexandra Damerau⁴, Paula Hoff³, Frank Buttgereit⁵ and Timo Gaber⁴, ¹Charité University Medicine Berlin, Berlin, Germany, ²Charit Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Inflamm-aging is a sterile, low-grade, chronic systemic inflammatory state characterized by an increase in proinflammatory cytokines involved in the development of most age-related diseases…
Abstract Number: 0158 • ACR Convergence 2021
The Influence of Age on the Prevalence of Inflammatory and Post-inflammatory MRI Lesions in the Sacroiliac Joints of Patients with and Without Axial Spondyloarthritis
Xenofon Baraliakos, Styliani Tsiami, Anna Kühn, Martin Fruth and Jürgen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is clinically characterized by chronic inflammatory back pain and by inflammatory and structural changes in the sacroiliac joint (SIJ) as assessed…
Abstract Number: 1678 • ACR Convergence 2021
Favorable Balance of Benefit and Harm of Long-Term, Low Dose Prednisolone Added to Standard Treatment in Rheumatoid Arthritis Patients Aged 65+: The Pragmatic, Multicenter, Placebo-Controlled GLORIA Trial
Maarten Boers¹, Linda Hartman¹, Daniela Opris-Belinski², Reinhard Bos³, Marc Kok⁴, Jose Pereira da Silva⁵, Ed Griep⁶, Ruth Klaasen⁷, Cornelia F. Allaart⁸, Paul Baudoin⁹, Hennie Raterman¹⁰, Zoltan Szekanecz¹¹, Frank Buttgereit¹², Pavol Masaryk¹³, L. Thomas Klausch¹, Sabrina Paolino¹⁴, Annemarie Schilder³, Willem Lems¹⁵ and Maurizio Cutolo¹⁴, ¹Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ²Carol Davila University, Bucharest, Romania, ³Medical Center Leeuwarden, Leeuwarden, Netherlands, ⁴Maasstad Hospital, Rotterdam, Netherlands, ⁵University of Coimbra | UC · Clínica Universitária de Reumatologia. Faculty of Medicine, Columbia, Portugal, ⁶Antonius Hospital, Sneek, Netherlands, ⁷Meander Medical Center, Amersfoort, Netherlands, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Reumazorg Flevoland, Emmeloord, Netherlands, ¹⁰Northwest Clinics, Alkmaar, Netherlands, ¹¹Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary, ¹²Charité – Universitätsmedizin Berlin, Berlin, Germany, ¹³National Institute for the Rheumatic Diseases, Bratislava, Slovakia, ¹⁴Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ¹⁵VUmc, Amsterdam, Netherlands
Background/Purpose: Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear. We studied the…
Abstract Number: 0352 • ACR Convergence 2021
Native American and African American Rheumatic Disease Patients Exhibit Accelerated Biological Aging Compared to European Americans
Joseph Kheir, Carla Guthridge, Nicolas Dominguez, Wade DeJager, Sarah Cooper, Joel Guthridge and Judith James, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The universal process of aging is associated with increased risk of disease and death as a result of changing physiologic and molecular processes. In…
Abstract Number: 1862 • ACR Convergence 2021
Clonal Hematopoiesis Across the Age Spectrum in Patients with Systemic Vasculitis
Kristina Wells¹, Fernanda Gutierrez-Rodrigues², Bhavisha Patel², Kaitlin Quinn³, Keith Sikora¹, Neal Young⁴ and Peter Grayson⁵, ¹National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ⁴National Heart, Lung, and Blood Institute (NHLBI), National Institues of Health, Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Clonal hematopoiesis (CH) is a pre-malignant state characterized by somatic mutations in hematologic precursor cells in genes associated with myeloid malignancies. Incidence of CH…
Abstract Number: 0375 • ACR Convergence 2021
Optimizing a Referral Strategy for Patients with a High Probability of Axial Spondyloarthritis:the Role of Age and Symptom Duration
Fabian Proft¹, Laura Spiller¹, Burkhard Muche², Mikhail Protopopov¹, Judith Rademacher¹, Valeria Rios Rodriguez¹, Murat Torgutalp¹, Denis Poddubnyy³ and Imke Redeker⁴, ¹Charité University Medicine Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ³Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ⁴German Rheumatism Research Centre (DRFZ), Berlin, Germany
Background/Purpose: One of the most important prerequisites for a timely diagnosis of axial spondyloarthritis (axSpA) is the early referral of a patient with back pain…
Abstract Number: 0584 • ACR Convergence 2021
High Number of Comorbidities and Concomitant Medications at Baseline in the Glucocorticoid Low-dose Outcome in Rheumatoid Arthritis (GLORIA) Study: An Older Population with Rheumatoid Arthritis
Maarten Boers¹, Linda Hartman¹, Daniela Opris-Belinski², Reinhard Bos³, Marc Kok⁴, Jose Pereira da Silva⁵, Eduard N Griep⁶, Ruth Klaasen⁷, Cornelia F. Allaart⁸, Paul Baudoin⁹, Hennie Raterman¹⁰, Zoltan Szekanecz¹¹, Frank Buttgereit¹², Pavol Masaryk¹³, L. Thomas Klausch¹, Sabrina Paolino¹⁴, Annemarie Schilder¹⁵, Willem Lems¹⁶ and Maurizio Cutolo¹⁴, ¹Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ²Carol Davila University, Bucharest, Romania, ³Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden, Netherlands, ⁴Maasstad Hospital, Rotterdam, Netherlands, ⁵University of Coimbra | UC · Clínica Universitária de Reumatologia. Faculty of Medicine, Columbia, Portugal, ⁶Antonius Hospital, Leeuwarden, Netherlands, ⁷Meander Medical Center, Amersfoort, Netherlands, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Reumazorg ZWN, Almere, Netherlands, ¹⁰Northwest Clinics, Alkmaar, Netherlands, ¹¹Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary, ¹²Charité – Universitätsmedizin Berlin, Berlin, Germany, ¹³National Institute for the Rheumatic Diseases, Bratislava, Slovakia, ¹⁴Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ¹⁵Medical Centre Leeuwarden, Leeuwarden, Netherlands, ¹⁶VUmc, Amsterdam, Netherlands
Background/Purpose: Older people are often underrepresented in trials because the generally high number of comorbid conditions (1). The objective of this abstract is to document…

« Previous Page
1
…
6
7
8
9
10
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].